Lanzamiento Enero 2027

Ensayo controlado aleatorizado2008

Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation

da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC

Journal of affective disorders · 135 citas

Cómo se estudió

Diseño
Ensayo controlado aleatorizado (indexado por PubMed)
Estudiado en
Personas
Resultado principal
Marcadores de salud y funcionamiento

Quién lo pagó

Financiación
Financiación independiente
Universidad u hospital
Universidade Federal do Paraná

Según 1 financiador declarado.

Publicación

Publicado
2008-05-16 · J Affect Disord · vol. 111 · número 2-3 · págs. 351–359
Editorial
Elsevier BV
Citado
205 citas · más que el 98% de estudios similares · 8.3× el promedio de su campo
Impacto
Entre el 10 % más citado de su campo
Referencias
56 trabajos
Acceso
De pago
Áreas de investigación
Fatty Acid Research and Health · Parkinson's Disease Mechanisms and Treatments · Treatment of Major Depression
Palabras clave
Parkinson's disease, depression, omega-3 fatty acids, fish oil supplementation, major depressive disorder, depression remission
MeSH
humans, parkinson disease, levodopa, mineral oil, fatty acids, omega-3, antiparkinson agents, antidepressive agents, placebos, treatment outcome, combined modality therapy, pilot projects, double-blind method, psychiatric status rating scales, personality inventory, comorbidity, dietary supplements, aged, middle aged, brazil, female, male, major depressive disorder

7 autores

  • Ticyana Moralez da Silva🇧🇷Universidade Federal do Paraná
  • Renato P. Munhoz
  • Cristiano Estevez Alvarez🇧🇷Hospital de Clínicas Universidade Federal do Paraná; Universidade Federal do Paraná
  • Katya Naliwaiko🇧🇷Universidade Federal do Paraná
  • Ágata Kiss🇧🇷Universidade Federal do Paraná
  • Roberto Andreatini🇧🇷Universidade Federal do Paraná
  • Anete Curte Ferraz🇧🇷 · autor de correspondenciaUniversidade Federal do Paraná

Resumen

El texto original del estudio, en el idioma en que se publicó.

Background

Effect of fish oil supplementation in parkinsonian patients with depression measured by Montgomery-Asberg Rating Scale (MADRS), the Clinical Global Impressions Scale (CGI) and Beck Depression Inventory (BECK).

Method

Double-blind, placebo-controlled study analyzed depression in 31 patients with Parkinson's Disease and Major Depression (DSM-IV). The patients were double-blind separated in 2 groups that received fish oil (containing omega-3 fatty acids) or mineral oil capsules for 3 months; each group was separated in 2 new groups: one taking antidepressant medication and another one not taking it.

Results

29 patients completed the 12-week trial, 58% were female and the mean age was 64.4 years old. Patients supplemented with fish oil showed a significant decrease in MADRS and CGI-Depression scores, and there was no difference among groups in BDI. 14 patients (42%) met criteria for > or = 50% reduction in MADRS score, 7 patients (22%) met criteria for remission (final MADRS total score < or = 12), and 2 patients (6%) discontinued supplementation of fish oil. HPLC analysis of fatty-acid profile showed increase of omega-3 fatty acid in the erythrocyte membrane of patients taking fish oil.

Conclusion

These results reveal that PD patients taking fish oil, with or without antidepressants, presented improvement in depressive symptoms and indicate that the intake of omega-3 can be used with an antidepressant effect or as adjuvant therapy with some other medication. This is a first pilot study with parkinsonian patients and omega-3 supplementation and requires replication in a larger sample.

Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

0 · nada10 · totalmente

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.

Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.